Tremfya vs. Cosentyx

Discussion in 'Janssen' started by anonymous, Dec 4, 2018 at 2:34 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    When is the data getting out? any idea which one will be shown better?
     

  2. anonymous

    anonymous Guest

    cosentyx crushed through 54 wk. at 102 wk all was equal. Also faster onset with cosentyx. It’s already out there. Google it.
     
  3. anonymous

    anonymous Guest

    You are chasing shadows. It’s called Risankizimab. You will be hearing a lot about it. Tremfa’s time of death is April 2019. Pasi scores? Try 90/90 at week 16. Game over.
     
  4. anonymous

    anonymous Guest

    At Week 16 PASI 90 was achieved by 75.3% patients receiving risankizumab versus 4.9% receiving placebo vs. 42% receiving ustekinumab
     
  5. anonymous

    anonymous Guest

    Drop the mike and walk away.
    Abbvie cuts the head off JnJs Dermatology. I’m gonna enjoy watching this one. In Particular I can’t Wait to see the managers get their collective tickets punched. Karma baby, karma.